Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine adjunctive therapy in major depressive disorder
2018-002782-19Phase 3Completed
- Sponsor
- Allergan
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cariprazine in major depressive disorder (MDD) (3 arms), sponsored by Allergan. Primary endpoint: Change in MADRS total score from baseline to Week 6. Started Feb 2019; status: completed.
02
Drugs
cariprazine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-002782-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002782-19.